Video
Author(s):
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events (AEs) in the treatment of patients with kidney cancer.
One of the things for genitourinary oncologists to keep in mind is that checkpoint inhibitors have a distinct toxicity profile. When AEs like pneumonitis or autoimmune colitis are detected, Ho says it would be beneficial to start steroid treatment earlier rather than later. These AEs can progress if they aren’t treated in their early stages. There are some emerging data from French groups as well as Dana-Farber Cancer Institute suggesting that even if steroid treatment is used, the durable responses associated with immunotherapy can be maintained.
With tyrosine kinase inhibitors (TKIs), Ho says it’s important to remember that dose adjustment is a viable option when unmanageable AEs present themselves. The scheduling regimen of tyrosine kinase inhibitors can also be adjusted.
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
2 Commerce Drive
Cranbury, NJ 08512